The current Long Term Debt to Equity is estimated to decrease to 0.0138. The current Debt to Equity Ratio is estimated to decrease to -0.11
We provide trade advice to complement the prevailing
expert consensus on Cleveland Biolabs. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Cleveland BioLabs Investment Alerts
Cleveland investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Cleveland BioLabs performance across your portfolios.Please check all
investment alerts for Cleveland
Cleveland BioLabs Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Cleveland value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cleveland BioLabs competition to find
correlations between indicators driving the intrinsic value of Cleveland.
An Additional Perspective On Cleveland BioLabs
This firm reported the previous year's revenue of 262.94
K. Net Loss for the year was (2.4
M) with loss before overhead, payroll, taxes, and interest of (428.13
K).
| 2020 | 2021 (projected) |
Interest Expense | 980.62 K | 974.89 K | Gross Profit | 262.94 K | 269.86 K |
Margins Breakdown
Cleveland profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Cleveland Biolabs itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Cleveland Biolabs profit margins.
| Operating Margin | (68.01) |
| EBITDA Margin | (9.31) |
| Gross Margin | 0.89 |
| Profit Margin | (9.36) |
Cleveland Biolabs Earnings Before Interest Taxes and Depreciation Amortization EBITDA is nearly stable at the moment. Also, Cleveland Biolabs Revenue Per Employee is decreasing over the last 8 years.
Our perspective of the current Cleveland Biolabs rise
Current treynor ratio is at 0.55. Cleveland Biolabs is displaying above-average volatility over the selected time horizon. Investors should scrutinize Cleveland Biolabs independently to ensure intended market timing strategies are aligned with expectations about Cleveland Biolabs volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cleveland Biolabs' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cleveland Biolabs' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Conclusion on Cleveland Biolabs
While some firms within the biotechnology industry are still a little expensive, even after the recent corrections, Cleveland Biolabs may offer a potential longer-term growth to stockholders. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither acquire new shares of Cleveland nor quit your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Cleveland Biolabs.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Cleveland BioLabs. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
